GPT and metabolic dysfunction-associated steatohepatitis: In clinical studies, patients with non-cirrhotic, but biopsy-confirmed MASH treated with an SGLT2-I had histological improvement, decreased lobular inflammation, fibrosis, and reduced serum AST and ALT [18, 19].